Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael, Martin-Regueira, Patricia, Sy, Oumar, Gurnani, Renuka, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387297/
https://www.ncbi.nlm.nih.gov/pubmed/32265500
http://dx.doi.org/10.1038/s41375-020-0805-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387297/
https://www.ncbi.nlm.nih.gov/pubmed/32265500
http://dx.doi.org/10.1038/s41375-020-0805-1

Ejemplares similares